413 filings
8-K
RZLT
Rezolute Inc
25 Apr 24
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
5:23pm
DEF 14A
RZLT
Rezolute Inc
Definitive proxy
12 Apr 24
9:31pm
8-K
RZLT
Rezolute Inc
14 Mar 24
Entry into a Material Definitive Agreement
5:00pm
8-K
RZLT
Rezolute Inc
11 Mar 24
Regulation FD Disclosure
5:03pm
8-K
RZLT
Rezolute Inc
22 Feb 24
Other Events
5:00pm
8-K
12iikt tw
13 Feb 24
Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
4:10pm
8-K
59k vlg6oxj32d6ks
29 Jan 24
Unregistered Sales of Equity Securities
5:15pm
8-K
8xxd2
14 Dec 23
Plans to report topline data mid-second quarter 2024
4:01pm
EFFECT
9d1m ic08rko
30 Nov 23
Notice of effectiveness
12:15am
CORRESP
h4jzkg99p59fed bzza7
27 Nov 23
Correspondence with SEC
12:00am
8-K
9or1i5c
22 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:35pm
UPLOAD
pt8oz0 hdl
20 Nov 23
Letter from SEC
12:00am
8-K
jcsk5nq7zhty
13 Nov 23
Rezolute Reports First Quarter Fiscal 2024 Results
4:13pm
8-K
oogmo6f
18 Oct 23
PRIME eligibility granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism
4:30pm
8-K
f2duy
13 Oct 23
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
4:47pm